Scarica l'app Stockscreener
139.71
0.42%
-0.59
Dopo l'orario di chiusura:
139.89
0.18
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$140.30
Aprire:
$139.61
Volume 24 ore:
4.72M
Relative Volume:
0.68
Capitalizzazione di mercato:
$173.41B
Reddito:
$29.45B
Utile/perdita netta:
$8.51B
Rapporto P/E:
20.60
EPS:
6.7823
Flusso di cassa netto:
$9.46B
1 W Prestazione:
+2.07%
1M Prestazione:
-6.88%
6M Prestazione:
+26.37%
1 anno Prestazione:
+24.86%
Intervallo 1D:
$138.64
$141.34
Intervallo di 1 settimana:
$133.89
$141.70
Portata 52W:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
139.71 | 173.41B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Kelleher Financial Advisors Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Meridian Investment Counsel Inc. Has $3.94 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Perpetual Ltd Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets - finance.yahoo.com
Gilead Sciences, Inc. (GILD) Galapagos NV,M&A CallSlideshow (NASDAQ:GILD) 2026-04-03 - Seeking Alpha
Gilead Sciences, Inc. $GILD Position Reduced by Aberdeen Group plc - MarketBeat
Layoff Tracker: Gilead Lays Off Employees at California Headquarters - BioSpace
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review - Ad Age
Gilead Sciences, Inc. (GILD.NE) recent insider transactions - Yahoo Finance UK
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - finance.yahoo.com
Gilead Refuses to Sell Groundbreaking HIV Prevention Drug to MSF - MarketScreener
HF Advisory Group LLC Buys 13,212 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
MSF Seeks Access to Breakthrough HIV Drug, But Gilead Refuses - allAfrica.com
Africa: Gilead Under Fire for Not Selling HIV Drug Lenacapavir to MSF - allAfrica.com
A Healthy Return: Drug Spin-off Nets Keymed Up To $320M - Benzinga
Bank Pictet & Cie Europe AG Purchases 136,605 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Banque Pictet & Cie SA Purchases 142,543 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Allspring Global Investments Holdings LLC Purchases 71,872 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
A Look At Gilead Sciences (GILD) Valuation After Recent Mixed Share Price Performance - Yahoo Finance
Nomura VIP Core Equity Series's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Gilead to acquire Ouro Medicines in $2.18B deal, expand inflammation pipeline - MSN
Morgan Stanley Reaffirms Overweight on Gilead Sciences, Inc. (GILD), Citing LEN Potential - MSN
Gilead extends Arcellx tender offer expiration date - MSN
Gilead (NASDAQ: ACLX) extends $115 per‑share tender, CVR pays $5 on condition - Stock Titan
Gilead Extends Tender Offer to Acquire Arcellx - Business Wire
Gilead Sciences Supports the LGBTQ+ Community in Oakland: Love Is the Answer - ACCESS Newswire
Gilead Sciences's Q1 2026 Earnings: What to Expect - Barchart
Gilead Sciences Inc Stock (GILD) Moved Up by 3.03% on Apr 1: Facts Behind the Movement - TradingKey
Gilead Sciences, Inc. $GILD Shares Acquired by Moody Lynn & Lieberson LLC - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Raised by Nisa Investment Advisors LLC - MarketBeat
Meyer Handelman Co. Has $41.33 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Shrier Wealth Management LLC Buys Shares of 14,244 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - finance.yahoo.com
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution - FinancialContent
Gilead Sciences Inc. stock rises Tuesday, still underperforms market - MarketWatch
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $160 - Moomoo
UBS reiterates Gilead Sciences stock rating on strong Yeztugo sales - Investing.com
Gilead Sciences Inc Stock (GILD) Moved Up by 3.62% on Mar 31: A Full Analysis - TradingKey
Gilead and its new HIV prevention drug are in the sights of a well-known humanitarian group - The Business Journals
MSF denied access to Gilead HIV-prevention drug - EU Reporter
J. Safra Sarasin Holding AG Trims Gilead Sciences Stake - National Today
Gilead (GILD) Enters Agreement to Acquire Ouro Medicines - GuruFocus
Gilead Sciences, Inc. $GILD Shares Bought by Mn Services Vermogensbeheer B.V. - MarketBeat
Boston Common Asset Management LLC Sells 15,833 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration - finance.yahoo.com
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Biotech deal-O-rama, Gilead and Tallon’s U.K. vision — a BioCentury podcast - biocentury.com
[Press release] Médecins Sans Frontières: Gilead refuses to sell groundbreaking HIV prevention drug to MSF - European AIDS Treatment Group
Gilead Sciences (NASDAQ: GILD) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.37%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):